Immunonutrition Supplementation in Head and Neck Cancer Patients Undergoing Cancer Treatment Study

Last updated: September 1, 2022
Sponsor: University of Malaya
Overall Status: Active - Not Recruiting

Phase

N/A

Condition

Human Papilloma Virus (Hpv)

Head And Neck Cancer

Nasopharyngeal Cancer

Treatment

N/A

Clinical Study ID

NCT05526040
HaNIS-1
  • Ages > 18
  • All Genders

Study Summary

This is a prospective, randomized, open-label intervention study to evaluate the effectiveness of immunonutrition supplementation in head and neck cancer (HNC) patients during cancer treatment.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Written informed consent obtained
  • Adult HNC patients, male or female, above 18 years of age
  • Primary HNC diagnosis, stage I to III; including: cancer of the nasopharynx,oropharynx, oral cavity, hypopharynx, or larynx, etc.
  • Referred and planned for curative-intent cancer treatment (radiotherapy andchemotherapy)
  • Eastern Cooperative Oncology Group (ECOG) performance status < 2

Exclusion

Exclusion Criteria:

  • Inability or unwillingness to provide written informed consent or comply with therequirements of the protocol
  • Patients with metastatic stage or recurring/relapse of cancer at same site
  • Planned for palliative cancer treatment
  • Underlying severe hepatic failure or renal dysfunction (eGFR < 30ml/min/1.73m2)
  • Underlying severe sepsis, neutropenia, immune-deficiencies or autoimmune diseases
  • Consumption of supplements or enriched foods containing immunonutrients (omega- 3,arginine or nucleotides) in the previous month prior to study; including dietarysupplements such as: fish oil capsules, arginine tablets/powder, RNA capsules, etc.
  • Known allergy or intolerance to components of the immunonutrition supplement (cow'smilk, fish or soy)
  • Enrolment in other cancer treatment trials

Study Design

Total Participants: 116
Study Start date:
November 01, 2022
Estimated Completion Date:
December 31, 2023

Study Description

The study population will be adult HNC patients receiving radiotherapy and chemotherapy treatment. The targeted number of subjects is 116 patients (58 subjects in each arm). Participants will be randomly assigned to receive standard medical nutrition therapy (individualized dietary assessment and counselling, and standard nutrition supplementation as necessary) or standard medical nutrition therapy with high energy, high protein, immunonutrient-enriched oral nutrition supplementation. Immunonutrition supplementation will begin 1 week prior to cancer treatment and continued throughout the cancer treatment, and to be taken in 3 servings/day. The study involves interviewing of subjects for dietary and nutrition assessment; measurement of weight, body composition, handgrip strength; and data collection from subjects' medical records.

Connect with a study center

  • Hospital Kuala Lumpur

    Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur 50586
    Malaysia

    Site Not Available

  • University of Malaya Medical Centre

    Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur 59100
    Malaysia

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.